Rockefeller Capital Management
GBT

Rockefeller Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Rockefeller Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-288,534
Closed -$9.22M – 4582
2022
Q2 		$9.22M Buy
288,534
+55,542
+24% +$1.63M 0.05% 366
2022
Q1 		$8.07M Buy
232,992
+9,086
+4% +$272K 0.04% 422
2021
Q4 		$6.55M Buy
223,906
+14,033
+7% +$435K 0.03% 469
2021
Q3 		$5.35M Buy
209,873
+46,392
+28% +$1.36M 0.03% 460
2021
Q2 		$5.72M Buy
163,481
+139,931
+594% +$5.46M 0.03% 418
2021
Q1 		$959K Buy
23,550
+11,300
+92% +$519K 0.01% 796
2020
Q4 		$530K Sell
12,250
-5,296
-30% -$261K ﹤0.01% 895
2020
Q3 		$967K Buy
17,546
+7,286
+71% +$463K 0.01% 606
2020
Q2 		$648K Buy
10,260
+10,171
+11,428% +$698K 0.01% 633
2020
Q1 		$5K Buy
89
+86
+2,867% +$5.76K ﹤0.01% 1981
2019
Q4 		$0 Buy
+3
New +$178 ﹤0.01% 2254

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Rockefeller Capital Management's GBT Position: Q3 2022 in Review

Rockefeller Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 288,534 shares — an estimated $9.22M sold.

Rockefeller Capital Management first reported a position in GBT in Q4 2019 and held it in 11 quarters. The position peaked at $9.22M in Q2 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Rockefeller Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 288,534 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $9.22M.
  • Rockefeller Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 11 quarters.
  • Rockefeller Capital Management's Global Blood Therapeutics, Inc. position peaked at $9.22M in Q2 2022.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Rockefeller Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.